Delhi, India
Delhi, India

Time filter

Source Type

News Article | May 15, 2017
Site: www.marketwired.com

Note to Editors: There is a photo associated with this press release. Drive 4 Smiles (D4S), a Starlight Children's Foundation event, will mark its fifth anniversary with its biggest fundraising celebration yet. Since its launch in 2013, D4S has been raising money and fulfilling the wishes of children afflicted with serious illnesses by giving them the opportunity to ride around a racetrack in some of the world's finest exotic automobiles. This year's 2017 edition will present two separate action-packed events. On June 4, drivers and their guests will gather at Audi West Island to embark on the D4S Poker Run, in which participants follow their "Road Captains" through some of Montreal's best back roads. At each stop, drivers will engage in activities, collect playing cards and, hopefully, hold the winning poker hand at the end of the run. On August 19, more than 120 of the most magnificent automobiles in the Montreal area are expected to participate in the Drive 4 Smiles Main Event, a roaring gathering of Lamborghinis, Aston Martins, Bentleys, Ferraris, Maseratis, Rolls Royces, Porsches, BMWs and other mighty machines at the Mirabel ICAR racetrack for a day of festivities, music, food and games. Car owners will host a special group of Starlight children, who will become co-pilots for a few precious moments to feel the excitement of racing around the track in a safe and controlled environment. Following the tours with children, ICAR's circuit will be made exclusively available to participating car owners to enjoy laps as fast as their skills will take them. Later that evening, Drive 4 Smiles will host an evening Rooftop Wrap Party at Porsche Prestige, where fabulous auction items will be up for grabs for the bidding pleasure of generous donors. "It is our fifth year producing this unique Starlight Children's Foundation event and we are deeply moved to see that it is only getting bigger for the benefit of the cause," stated Stewart Kahan, Chairman D4S Canada. "Luxury car owners share many tastes and are frequent contributors to charities. What makes Drive 4 Smiles so different is the opportunity to spend time with children who are the actual beneficiaries of the fundraising efforts, and to see the joy and wonder in their faces as they escape for a moment from the difficult medical treatments that consume their daily lives. It is a very rewarding experience on an emotional level." Since its launch five years ago in Montreal, Drive 4 Smiles and its donors have raised $1.2 million for Starlight Children's Foundation. The 2017 event is still open to new exotic car owners wishing to make an impact and share good times with fellow automobile aficionados. The drivers' registration fee is $1,800, which participants may donate personally or fundraise among friends. Partial tax receipts will be issued to self-sponsored drivers. For registration: http://www.d4scanada.com/ Starlight Children's Foundation™ Canada is part of Starlight's global network, serving seriously ill children and their families through partnerships with more than 160 healthcare facilities. Over the past 25 years, Starlight has become a leading global charity that partners with experts to improve the life and health of kids and families around the world. Collaborating with innovators in pediatric healthcare, entertainment and technology, Starlight provides a unique blend of family-centered programs and services from hospital to home. TD Bank Group invests in communities in order to bring positive change in the places where it operates and where its customers and employees live and work. In 2016, TD donated more than $102.8 million to community organizations in Canada, the United States and the United Kingdom. In Canada, TD focuses on education and financial literacy, creating opportunities for young people and the environment. For further information, please visit www.td.com/corporate-responsibility. To view the photo associated with this press release, please visit the following link:


News Article | May 22, 2017
Site: globenewswire.com

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in three presentations at the 30th International Conference on Antiviral Research (ICAR) held on May 21-25, 2017 in Atlanta, GA. These presentations feature preclinical data from multiple Arbutus pipeline programs that highlight the potential of Arbutus' therapeutic candidates to impair HBV viral functions and demonstrate additive to synergistic activity when combining Arbutus assets with approved HBV therapies. “Systematic In Vitro Evaluation of Current and Experimental Hepatitis B Therapeutics: Potential Utility for Combinations Exploiting Multiple and Diverse Mechanisms of Action” by Andrea Cuconati, Director of Virology In preclinical studies, multiple clinical and preclinical Arbutus direct acting antiviral agents tested in combination with nucleoside/nucleotide analogues (NAs) or interferon α-2a (IFN) standard of care therapeutics resulted in either additive or synergistic effects, suppressing multiple elements of HBV including HBsAg, HBeAg and HBV DNA. The results confirm the utility of Arbutus’ agents in clinical combinations with standard of care.  Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. “Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B” by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery In preclinical studies, STING activation results in control of HBV. Repeated STING activation yielded cumulative reductions in HBV DNA and HBcAg across a 7-day course of study. Type I IFN and cytokine induction may activate innate immune cells and T cell priming to potentially break HBV immune tolerance. These findings provide proof of concept that targeting STING in chronic HBV infection may contribute to viral control and complement the immune modulatory programs underway at Arbutus. “Viral Hepatitis – The Search for a Cure” by Dr. Mike Sofia, Chief Scientific Officer An introduction to the HBV landscape and an overview of the potential new therapies that may overcome the challenge of persistent chronic HBV infection and achieve a functional cure. These presentations can be accessed by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations. In conjunction with ICAR, Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer has been awarded the International Society of Antiviral Research (ISAR) Gertrude Elion Award for his outstanding contributions to the antiviral field through his development of a landmark hepatitis C virus (HCV) treatment. “It is a great honor to receive the ISAR Gertrude Elion Award for my work that led to the discovery of sofosbuvir, which is the backbone of the curative standard of care for HCV. Arbutus is following a similar pathway by developing multiple therapeutic agents to achieve a cure for chronic HBV,” said Dr. Sofia. “We are pleased to be presenting more encouraging data from our preclinical drug combination studies that support the utility of our proprietary HBV candidates in combination with the current standard of care. We continue to employ a range of HBV models to examine the potential use and mechanistic complementarity of our HBV agents in these combination regimens. Arbutus has built a robust pipeline of HBV product candidates to support this strategy.” Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com. This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about the potential of Arbutus' therapeutic candidates to impair HBV viral functions; targeting STING in chronic HBV infection contributing to viral control and complementing the immune modulatory programs underway at Arbutus; nominating a 2nd generation capsid assembly development candidate this year; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.


News Article | May 22, 2017
Site: globenewswire.com

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in three presentations at the 30th International Conference on Antiviral Research (ICAR) held on May 21-25, 2017 in Atlanta, GA. These presentations feature preclinical data from multiple Arbutus pipeline programs that highlight the potential of Arbutus' therapeutic candidates to impair HBV viral functions and demonstrate additive to synergistic activity when combining Arbutus assets with approved HBV therapies. “Systematic In Vitro Evaluation of Current and Experimental Hepatitis B Therapeutics: Potential Utility for Combinations Exploiting Multiple and Diverse Mechanisms of Action” by Andrea Cuconati, Director of Virology In preclinical studies, multiple clinical and preclinical Arbutus direct acting antiviral agents tested in combination with nucleoside/nucleotide analogues (NAs) or interferon α-2a (IFN) standard of care therapeutics resulted in either additive or synergistic effects, suppressing multiple elements of HBV including HBsAg, HBeAg and HBV DNA. The results confirm the utility of Arbutus’ agents in clinical combinations with standard of care.  Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. “Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B” by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery In preclinical studies, STING activation results in control of HBV. Repeated STING activation yielded cumulative reductions in HBV DNA and HBcAg across a 7-day course of study. Type I IFN and cytokine induction may activate innate immune cells and T cell priming to potentially break HBV immune tolerance. These findings provide proof of concept that targeting STING in chronic HBV infection may contribute to viral control and complement the immune modulatory programs underway at Arbutus. “Viral Hepatitis – The Search for a Cure” by Dr. Mike Sofia, Chief Scientific Officer An introduction to the HBV landscape and an overview of the potential new therapies that may overcome the challenge of persistent chronic HBV infection and achieve a functional cure. These presentations can be accessed by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations. In conjunction with ICAR, Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer has been awarded the International Society of Antiviral Research (ISAR) Gertrude Elion Award for his outstanding contributions to the antiviral field through his development of a landmark hepatitis C virus (HCV) treatment. “It is a great honor to receive the ISAR Gertrude Elion Award for my work that led to the discovery of sofosbuvir, which is the backbone of the curative standard of care for HCV. Arbutus is following a similar pathway by developing multiple therapeutic agents to achieve a cure for chronic HBV,” said Dr. Sofia. “We are pleased to be presenting more encouraging data from our preclinical drug combination studies that support the utility of our proprietary HBV candidates in combination with the current standard of care. We continue to employ a range of HBV models to examine the potential use and mechanistic complementarity of our HBV agents in these combination regimens. Arbutus has built a robust pipeline of HBV product candidates to support this strategy.” Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com. This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about the potential of Arbutus' therapeutic candidates to impair HBV viral functions; targeting STING in chronic HBV infection contributing to viral control and complementing the immune modulatory programs underway at Arbutus; nominating a 2nd generation capsid assembly development candidate this year; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.


News Article | May 22, 2017
Site: globenewswire.com

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in three presentations at the 30th International Conference on Antiviral Research (ICAR) held on May 21-25, 2017 in Atlanta, GA. These presentations feature preclinical data from multiple Arbutus pipeline programs that highlight the potential of Arbutus' therapeutic candidates to impair HBV viral functions and demonstrate additive to synergistic activity when combining Arbutus assets with approved HBV therapies. “Systematic In Vitro Evaluation of Current and Experimental Hepatitis B Therapeutics: Potential Utility for Combinations Exploiting Multiple and Diverse Mechanisms of Action” by Andrea Cuconati, Director of Virology In preclinical studies, multiple clinical and preclinical Arbutus direct acting antiviral agents tested in combination with nucleoside/nucleotide analogues (NAs) or interferon α-2a (IFN) standard of care therapeutics resulted in either additive or synergistic effects, suppressing multiple elements of HBV including HBsAg, HBeAg and HBV DNA. The results confirm the utility of Arbutus’ agents in clinical combinations with standard of care.  Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. “Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B” by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery In preclinical studies, STING activation results in control of HBV. Repeated STING activation yielded cumulative reductions in HBV DNA and HBcAg across a 7-day course of study. Type I IFN and cytokine induction may activate innate immune cells and T cell priming to potentially break HBV immune tolerance. These findings provide proof of concept that targeting STING in chronic HBV infection may contribute to viral control and complement the immune modulatory programs underway at Arbutus. “Viral Hepatitis – The Search for a Cure” by Dr. Mike Sofia, Chief Scientific Officer An introduction to the HBV landscape and an overview of the potential new therapies that may overcome the challenge of persistent chronic HBV infection and achieve a functional cure. These presentations can be accessed by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations. In conjunction with ICAR, Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer has been awarded the International Society of Antiviral Research (ISAR) Gertrude Elion Award for his outstanding contributions to the antiviral field through his development of a landmark hepatitis C virus (HCV) treatment. “It is a great honor to receive the ISAR Gertrude Elion Award for my work that led to the discovery of sofosbuvir, which is the backbone of the curative standard of care for HCV. Arbutus is following a similar pathway by developing multiple therapeutic agents to achieve a cure for chronic HBV,” said Dr. Sofia. “We are pleased to be presenting more encouraging data from our preclinical drug combination studies that support the utility of our proprietary HBV candidates in combination with the current standard of care. We continue to employ a range of HBV models to examine the potential use and mechanistic complementarity of our HBV agents in these combination regimens. Arbutus has built a robust pipeline of HBV product candidates to support this strategy.” Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com. This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about the potential of Arbutus' therapeutic candidates to impair HBV viral functions; targeting STING in chronic HBV infection contributing to viral control and complementing the immune modulatory programs underway at Arbutus; nominating a 2nd generation capsid assembly development candidate this year; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.


News Article | May 22, 2017
Site: globenewswire.com

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in three presentations at the 30th International Conference on Antiviral Research (ICAR) held on May 21-25, 2017 in Atlanta, GA. These presentations feature preclinical data from multiple Arbutus pipeline programs that highlight the potential of Arbutus' therapeutic candidates to impair HBV viral functions and demonstrate additive to synergistic activity when combining Arbutus assets with approved HBV therapies. “Systematic In Vitro Evaluation of Current and Experimental Hepatitis B Therapeutics: Potential Utility for Combinations Exploiting Multiple and Diverse Mechanisms of Action” by Andrea Cuconati, Director of Virology In preclinical studies, multiple clinical and preclinical Arbutus direct acting antiviral agents tested in combination with nucleoside/nucleotide analogues (NAs) or interferon α-2a (IFN) standard of care therapeutics resulted in either additive or synergistic effects, suppressing multiple elements of HBV including HBsAg, HBeAg and HBV DNA. The results confirm the utility of Arbutus’ agents in clinical combinations with standard of care.  Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. “Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B” by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery In preclinical studies, STING activation results in control of HBV. Repeated STING activation yielded cumulative reductions in HBV DNA and HBcAg across a 7-day course of study. Type I IFN and cytokine induction may activate innate immune cells and T cell priming to potentially break HBV immune tolerance. These findings provide proof of concept that targeting STING in chronic HBV infection may contribute to viral control and complement the immune modulatory programs underway at Arbutus. “Viral Hepatitis – The Search for a Cure” by Dr. Mike Sofia, Chief Scientific Officer An introduction to the HBV landscape and an overview of the potential new therapies that may overcome the challenge of persistent chronic HBV infection and achieve a functional cure. These presentations can be accessed by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations. In conjunction with ICAR, Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer has been awarded the International Society of Antiviral Research (ISAR) Gertrude Elion Award for his outstanding contributions to the antiviral field through his development of a landmark hepatitis C virus (HCV) treatment. “It is a great honor to receive the ISAR Gertrude Elion Award for my work that led to the discovery of sofosbuvir, which is the backbone of the curative standard of care for HCV. Arbutus is following a similar pathway by developing multiple therapeutic agents to achieve a cure for chronic HBV,” said Dr. Sofia. “We are pleased to be presenting more encouraging data from our preclinical drug combination studies that support the utility of our proprietary HBV candidates in combination with the current standard of care. We continue to employ a range of HBV models to examine the potential use and mechanistic complementarity of our HBV agents in these combination regimens. Arbutus has built a robust pipeline of HBV product candidates to support this strategy.” Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com. This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about the potential of Arbutus' therapeutic candidates to impair HBV viral functions; targeting STING in chronic HBV infection contributing to viral control and complementing the immune modulatory programs underway at Arbutus; nominating a 2nd generation capsid assembly development candidate this year; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.


Deux courses spectaculaires et un première fin de semaine de complétée pour le comédien Michel Barrette qui effectuait ses débuts officiels MISSISSAUGA, ON--(Marketwired - 28 mai 2017) - Une semaine seulement après son premier rendez-vous de la saison 2017, les pilotes de la Coupe Nissan Micra étaient en piste cette fin de semaine au Circuit Mont-Tremblant pour deux nouvelles courses disputées dans le cadre de la Classique de printemps. Deux courses spectaculaires à souhait, remportées par Olivier Bédard le samedi puis par Xavier Coupal le dimanche, et qui marquaient aussi les grands débuts à titre de pilote de Coupe Nissan Micra du populaire comédien et humoriste québécois Michel Barrette. Après une journée d'essais libres fructueux pour tous les pilotes le vendredi, la journée de samedi, sous un ciel nuageux mais une piste toujours sèche, débutait par la traditionnelle séance de qualification. Lauréat des deux premières courses de la saison, en Ontario la fin de semaine passée, Jean-Michel Isabelle décrochait la pole position devant les champions 2016 (Xavier Coupal) et 2015 (Olivier Bédard). Seule pilote féminine cette saison dans la série, Valérie Limoges affichait ses ambitions en décrochant le quatrième meilleur temps, devant Kevin King, Stéfan Gauthier, le premier de la classe Senior Metod Topolnik, l'Australien Keishi Ayukai, Nicolas Touchette et le Britannique Jake Exton. Chez les recrues, Vincent Doyle devançait Nicolas Barrette. En après-midi, vingt-deux pilotes prenaient le départ de la course, au volant de leurs Nissan Micra quasiment de série, devant les fans regroupés le long du circuit. En tête, le duel entre Isabelle et Coupal se solda par un accrochage, laissant Valérie Limoges aux commandes peu avant la mi-course. Mais dès la relance, Bédard surprit sa coéquipière pour filer vers sa première victoire de la saison. Kevin King et Valérie Limoges complètent le podium, devant Ayukai, brillant pour ses débuts au Circuit Mont-Tremblant, et Normand Boyer, lauréat de la classe Sénior pour une troisième fois de suite. Chez les recrues, Vincent Doyle décroche une première victoire, devant Jake Exton et Austin Riley. Michel Barrette complète pour sa part sa première course automobile officielle en carrière en seizième place toutes-catégories, septième classe Sénior et quatrième des recrues. Dimanche, Coupal et Bédard se partageaient la première ligne de départ et leur domination a duré toute la course. Ils terminent dans cet ordre, le champion 2016 décrochant à son tour sa première victoire de la saison. La bataille pour la troisième place a été plus que spectaculaire, les positions changeant au fil des tours. Qualifiée neuvième, Valérie Limoges a réalisé une superbe remontée, pour compléter ainsi le triomphe de l'équipe Total Canada qui voit ses trois pilotes sur le podium. Les coéquipiers de l'équipe Sorel-Tracy Nissan, Kevin King et Stéfan Gauthier complètent le Top 5, devant Jean-Michel Isabelle et Metod Topolnik, qui décroche sa première victoire en classe Sénior, devant Normand Boyer et Frédéric Bernier. Chez les recrues, le lauréat est cette fois Jake Exton. Quant à Michel Barrette, il a livré une lutte de tous les instants à son fils Nicolas, le père et le fils s'échangeant la quinzième position à pas moins de six reprises. C'est finalement Nicolas qui a eu le meilleur, franchissant la ligne d'arrivée avec trois dixièmes de seconde d'avance sur son père ! Tout comme au Canadian Tire Motorsport Park une semaine plus tôt, de nombreux propriétaires de Nissan Micra avaient répondu à l'invitation de Nissan Canada d'assister gratuitement à cette Classique de printemps 2017. Rappelons que lors de chaque événement de la série, Nissan Canada invite les propriétaires de Micra. Il leur suffit simplement de s'inscrire trois semaines avant chaque épreuve sur le site www.coupemicra.com/inscriptionevenement pour recevoir deux billets et un accès stationnement. Au Circuit Mont-Tremblant, les heureux propriétaires sur place ont en plus eu l'occasion d'effectuer un tour de piste en parade, samedi puis dimanche. Ils étaient une cinquantaine à avoir répondu présent et, pour la plupart d'entre eux, il s'agissait d'un premier contact avec le sport automobile et ils ont été époustouflés de voir les performances de leur petite Micra sur le circuit et la qualité du spectacle offert par les pilotes! Pour son prochain événement, la grande famille de la Coupe Nissan Micra retrouvera le Circuit Mont-Tremblant, du 21 au 23 juillet. Mais auparavant, un événement destiné à faire connaître la série au grand public, et même permettre de piloter les voitures de course, sera tenu au Circuit ICAR, à Mirabel, le samedi 18 juin prochain. Tous les détails sur le site www.nissan.ca/coupemicra. Pour les résultats complets des courses disputées au Circuit Mont-Tremblant, visitez le site : http://www.coupemicra.com/2017-Resultats_Courses?RID=23 (course 3) http://www.coupemicra.com/2017-Resultats_Courses?RID=24 (course 4) Pour plus d'information sur la Coupe Nissan Micra, consultez : www.nissan.ca/coupemicra. Calendrier de la saison 2017 de la Coupe Nissan Micra : Nissan North America En Amérique du Nord, les activités de Nissan comprennent le design automobile, la conception technique, le financement aux entreprises et aux particuliers, la vente, la commercialisation, la distribution et la fabrication. Nissan s'emploie à assainir l'environnement dans le cadre de son Programme vert et a été reconnue partenaire ENERGY STARMD chaque année depuis 2010 par la United States Environmental Protection Agency. Pour obtenir de plus amples renseignements sur Nissan en Amérique du Nord et sur la gamme complète de véhicules Nissan et INFINITI, veuillez consulter les sites suivants : www.NissanUSA.com et www.INFINITIUSA.com. Vous pouvez aussi consulter les sites de nouvelles des États-Unis aux adresses suivantes : NissanNews.com et INFINITINews.com. Nissan Motor Co., Ltd. Nissan est un constructeur automobile mondial offrant une gamme complète composée de 60 modèles sous les marques Nissan, INFINITI et Datsun. Au cours de l'exercice 2016, l'entreprise a vendu plus de 5.63 millions de véhicules dans le monde, générant un chiffre d'affaires de 11.72 milliards de yens. Nissan conçoit, fabrique et commercialise le véhicule entièrement électrique le plus vendu mondialement de l'histoire, la Nissan LEAF. Son siège social mondial, situé à Yokohama, au Japon, gère les activités dans six régions : l'ANASE et l'Océanie; l'Afrique, le Moyen-Orient et l'Inde; la Chine; l'Europe; l'Amérique latine et l'Amérique du Nord. Nissan a un effectif global de 247 500 personnes et est associé au constructeur français Renault depuis 1999 et à Mitsubishi Motors depuis 2016 en vertu de l'Alliance Renault-Nissan. En 2016, Nissan a racheté 34 % de Mitsubishi Motors, qui est devenu par la suite le troisième membre à part entière de l'Alliance -un groupement dont les ventes annuelles combinées représentent presque 10 millions d'unités par an. Pour obtenir de plus amples renseignements sur nos produits, services et sur notre engagement envers une mobilité durable, consultez notre site Web à l'adresse suivante : http://www.nissan-global.com/EN/ (en anglais). Vous pouvez également nous suivre sur Twitter @NissanMotor. Nissan Canada Inc. Nissan Canada Inc. (NCI) est la filiale canadienne de vente, de commercialisation et de distribution de Nissan Motor Limited et de Nissan North America, Inc. NCI emploie directement 306 personnes à temps plein dans ses bureaux de Vancouver (Colombie-Britannique), de Mississauga (Ontario) et de Kirkland (Québec). Le Canada compte 194 concessionnaires Nissan indépendants, 41 concessionnaires INFINITI et 45 concessionnaires de véhicules commerciaux Nissan. Pionnière de la mobilité zéro émission, Nissan est passée à l'histoire avec le lancement de la Nissan LEAF, premier véhicule entièrement électrique abordable et commercialisé à grande échelle. Ce modèle a reçu plusieurs récompenses internationales, notamment les prestigieux prix de Voiture européenne de l'année 2011 et de Voiture mondiale de l'année 2011. Pour obtenir de plus amples renseignements sur les activités de Nissan au Canada ainsi que sur la gamme complète des véhicules Nissan et INFINITI, veuillez consulter les sites www.nissan.ca et www.INFINITI.ca. Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-1-42ae6fe9ac4baaac873a77813cc536fb.JPG Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-2-0ed8a28ec453a2d0815ce719bd7759a8.JPG Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-3-8c5b5b76b48384db9f788c5175948cd6.JPG Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-4-6f20f035b0e8bbf48efa33bd086bcd29.JPG Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-5-a0d170f74b4ab23faa0b6f27f1fc6597.JPG Image disponible: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-6-fcb56469747ebaf89189b26fc24eb5b7.jpg


News Article | May 28, 2017
Site: www.marketwired.com

Two spectacular races and a successful weekend for actor Michel Barrette's official debut MISSISSAUGA, ON--(Marketwired - May 28, 2017) - Just one week after the first race weekend of the 2017 season, the Nissan Micra Cup drivers were back on the track this weekend at the Circuit Mont-Tremblant for the Spring Classic. The second race weekend of the season marked popular actor and comedian Michel Barrette's debut as a Nissan Micra Cup driver, and featured two action-packed races. The first race was won by Olivier Bédard on Saturday and the second race was won by Xavier Coupal on Sunday. After a productive day of practice sessions on Friday, the Nissan Micra Cup drivers kicked off the first day of racing on Saturday with the traditional qualifying sessions, under an overcast but dry sky. Winner of the first two races of the season, Jean-Michel Isabelle earned himself the pole position ahead of 2016 champion Xavier Coupal and 2015 champion Olivier Bédard. Valérie Limoges, the only female driver competing this season, made her mark and claimed fourth fastest time ahead of Kevin King, Stéfan Gauthier, top senior class driver Metod Topolnik, Australian Keishi Ayukai, Nicolas Touchette and British driver Jake Exton. Vincent Doyle was the fastest rookie, followed by Nicolas Barrette. In the afternoon, 22 drivers got behind the wheel of their practically stock Nissan Micras, in front of numerous fans lining the track, and competed in the first race of the weekend. A duel between Jean-Michel Isabelle and Xavier Coupal caused a minor incident at the front of the pack, allowing Valérie Limoges to take the lead halfway through the race. As soon as the race restarted, Olivier Bédard surprised his fellow drivers and claimed his first victory of the season. Kevin King and Valérie Limoges completed the podium, ahead of Keishi Ayukai, who performed extremely well for his first time competing at the Circuit Mont-Tremblant, and Normand Boyer, winner of the senior class for the third consecutive time. For the rookies, Vincent Doyle earned his first victory ahead of Nicolas Barrette and Austin Riley. Michel Barrette also performed well for his first official motorsport race, finishing seventeenth overall, seventh in the senior class, and fourth amongst the rookies. On Sunday, Coupal and Bédard shared the starting line and their battle lasted throughout the duration of the race. Coupal, the 2016 champion, finished ahead of Bédard claiming his first victory of the 2017 season. The fight for the podium's third place was also very intense, with positions constantly changing every lap. Qualifying in ninth place, Valérie Limoges had an excellent climb up the leaderboard, rounding out a first, second and third finish for the Total Canada team's drivers. The Sorel-Tracy Nissan teammates Kevin King and Stéfan Gauthier completed the top five, ahead of Jean-Michel Isabelle and Metod Topolnik, who won the senior class for the first time, ahead of Normand Boyer. Among the rookies, Jake Exton claimed first place following Sunday's race. Michel Barrette finished in sixteenth place following a spectacular battle with his son Nicolas, with three thousandths of a second separating both drivers at the finish line. Similar to the first race weekend at the Canadian Tire Motorsport Park last week, numerous Nissan Micra owners attended the second race weekend at the Circuit Mont-Tremblant. For the 2017 season, Nissan Canada is inviting Nissan Micra owners to attend all race weekends free of charge. In order to take advantage of this opportunity, Nissan Micra owners must register three weeks in advance at http://www.micracup.com/eventregistration/. All registered Nissan Micra owners will receive two free tickets and parking access for the race weekend of their choice. The Nissan Micra owners that attended the race weekend at Circuit Mont-Tremblant had the opportunity to do a parade lap of the track on both Saturday and Sunday. Nearly 50 Nissan Micra owners were present and for most of them, it was their first introduction to motorsports. It was also an exciting opportunity for them to witness how their Micras perform on the track, in the hands of the very talented Nissan Micra Cup drivers. The Nissan Micra Cup community will reconvene at the Circuit Mont-Tremblant for the third race weekend of the season, from July 21 to 23. Prior to that, a discovery day will be held for Nissan Micra Cup fans at Mirabel's Circuit ICAR on June 18. For more information about this exciting event, please visit http://www.micracup.com/main. Overall championship standings after four races: http://www.micracup.com/2017-Results_ClassGen. For more information on the Nissan Micra Cup, please visit: http://www.micracup.com/main. About Nissan North America In North America, Nissan's operations include automotive styling, engineering, consumer and corporate financing, sales and marketing, distribution and manufacturing. Nissan is dedicated to improving the environment under the Nissan Green Program and has been recognized annually by the U.S Environmental Protection Agency as an ENERGY STAR® Partner of the Year since 2010. More information on Nissan in North America and the complete line of Nissan and INFINITI vehicles can be found online at www.NissanUSA.com and www.INFINITIUSA.com, or visit the U.S. media sites NissanNews.com and INFINITINews.com. About Nissan Motor Co., Ltd. Nissan is a global full-line vehicle manufacturer that sells more than 60 models under the Nissan, Infiniti and Datsun brands. In fiscal year 2016, the company sold 5.63 million vehicles globally, generating revenue of 11.72 trillion yen. Nissan engineers, manufactures and markets the world's best-selling all-electric vehicle in history, the Nissan LEAF. Nissan's global headquarters in Yokohama, Japan, manages operations in six regions: ASEAN & Oceania; Africa, Middle East & India; China; Europe; Latin America; and North America. Nissan has a global workforce of 247,500 and has been partnered with French manufacturer Renault under the Renault-Nissan Alliance since 1999. In 2016, Nissan acquired a 34% stake in Mitsubishi Motors, which became the third full member of the Alliance -- a grouping with combined annual sales of almost 10 million units a year. For more information on our products, services and commitment to sustainable mobility, visit our website at http://www.nissan-global.com/EN/. You can also follow @NissanMotor on Twitter. About Nissan Canada Inc. Nissan Canada Inc. (NCI) is the Canadian sales, marketing and distribution subsidiary of Nissan Motor Limited and Nissan North America, Inc. NCI directly employs 306 full-time staff across offices in Vancouver (BC), Mississauga (ON), and Kirkland (QC). There are 194 independent Nissan dealerships, 41 INFINITI retailers and 45 Nissan Commercial Vehicle dealers across Canada. A pioneer in zero emission mobility, Nissan made history with the introduction of the Nissan LEAF, the first affordable, mass-market, pure-electric vehicle and winner of numerous international accolades including the prestigious 2011 European Car of the Year and World Car of the Year awards. More information about Nissan in Canada and the complete line of Nissan and INFINITI vehicles can be found online at www.nissan.ca and www.INFINITI.ca. Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-1-42ae6fe9ac4baaac873a77813cc536fb.JPG Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-2-0ed8a28ec453a2d0815ce719bd7759a8.JPG Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-3-8c5b5b76b48384db9f788c5175948cd6.JPG Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-4-6f20f035b0e8bbf48efa33bd086bcd29.JPG Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-5-a0d170f74b4ab23faa0b6f27f1fc6597.JPG Image Available: http://www.marketwire.com/library/MwGo/2017/5/28/11G139831/Images/Photo-6-fcb56469747ebaf89189b26fc24eb5b7.jpg


Simona Onori, an assistant professor at Clemson University, has received a $500,000 Faculty Early Career Development Program (CAREER) award from the National Science Foundation to advance her work to develop integrated modeling and control for aftertreatment systems to reduce fine-particle emissions from gasoline direct injection (GDI) engines. GDI engines now account for about 60% of the US market, and their use worldwide is forecast to grow. GDI engines have better fuel economy and lower carbon-dioxide emissions than more conventional port fuel injection engines; however, the technology results in higher fine-particle emissions. The research Onori and her team are doing focuses on gasoline particulate filters (GPF). While the dynamics of diesel engine particulate filters (DPF) are well understood, particulates produced in GDI engines have substantially different characteristics. Onori notes that an integrated approach to reduce gasoline particulates is necessary because engine operating conditions determine oxygen and fuel content and temperature of the exhaust gas, which influence the output of the catalytic converter, which in turn governs soot accumulation and oxidation in particulate filters. Onori’s project is intended to enable new exhaust gas aftertreatment technologies for GDI engines based on a modeling framework at the intersection of macroscale modeling, numerical simulations and optimization theory. System-level models of the engine, catalytic converter, and gasoline particulate filter will be integrated across length scales, incorporating effects ranging from clogging and regeneration of the filter pores, to continuum gas flow in the exhaust manifold. The framework will enable formulation of low-order models of aftertreatment systems suitable for real-time optimization-based control, based on systematic and rigorous reduction of continuum models while maintaining accuracy and fidelity. The project is intended to improve substantially macro-scale representations of soot-layer physical properties and pore-scale loading and regeneration phenomena in particulate filters. The results will be used to design physics-based estimators for robust control of advanced aftertreatment systems. The resulting engine-control strategies would be programmed into the engine control unit. Onori and her team also plan to develop a control program that would enable three complex systems—the filter, exhaust and three-way catalyst—to work together. Onori will present aspects of her work on emissions controls at the upcoming 2017 American Control Conference in Seattle in May. Among her papers will be a discussion of the development of a two-dimensional (2-D), multi-channel, GPF system model and a multi-scale modeling framework to resolve mass, energy, and momentum transport equations of the exhaust gases in a GPF. Onori started working on emission control problems right after joining the Clemson University International Center for Automotive Research (CU-ICAR) in 2014. She was the principal investigator of an industry-sponsored project aimed at developing model-based control strategies for the new advanced aftertreatment systems.

Loading ICAR collaborators
Loading ICAR collaborators